4 enrolling by invitation. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Enrolling by invitation 4 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chronic Exogenous Ketosis in HFpEF Exogenous Ketone Drink, Placebo - Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction | Phase 2 | Enrolling by invitation | Duke University | 20 | 2025-07-28 | 2026-10-14 |
| A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion HSK31858, Placebo - Asthma Bronchiale, Bronchiectasis | Phase 2 | Enrolling by invitation | Haisco Pharmaceutical Group Co., Ltd. | 309 | 2024-12-10 | 2025-02-20 |
| A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma HSK31858, Placebo - Bronchial Asthma | Phase 2 | Enrolling by invitation | Haisco Pharmaceutical Group Co., Ltd. | 219 | 2024-10-22 | 2024-12-24 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma Lunsekimig - Asthma | Phase 2 | Enrolling by invitation | Sanofi | 900 | 2024-09-30 | 2026-09-21 |
Asthma (2) · Bronchiectasis (1) · Bronchiolitis Obliterans Syndrome (1) · Heart Failure (1) · Heart Failure, Diastolic (1) · Ketosis (1) · Motor Activity (1) · Pulmonary Disease, Chronic Obstructive (1)
Bronchial Diseases (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Immune System Diseases (3) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Respiratory Hypersensitivity (2) · Acid-Base Imbalance (1) · Acidosis (1) · Behavior (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Cardiovascular Diseases (1)
Ketones (1)
Haisco Pharmaceutical Group Co., Ltd. (2) · Duke University (1) · Sanofi (1)
China (3) · United States (2) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Germany (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Mexico (1) · Poland (1) · South Africa (1)
2025 (1)